The Medical Letter on Drugs and Therapeutics
Ziconotide (Prialt) for Chronic Pain
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved ziconotide (Prialt – Elan) intrathecal infusion for management of severe chronic pain in patients who are intolerant of or refractory to other treatments. Ziconotide is a synthetic neuronal N-type calcium channel blocker. It is intended for use with a programmable implanted microinfusion device, but an external microinfusion device can be used temporarily.

INTRATHECAL TREATMENT OF PAIN — Intraspinal (intrathecal or epidural) administration of analgesics is usually tried only when standard treatments have failed.1 Morphine (Infumorph, Astramorph) is approved for treatment of chronic pain by intrathecal administration. Baclofen (Lioresal) is approved for intrathecal treatment of spasticity. Other opioids, ketamine (Ketalar, and others), midazolam (Versed, and others), clonidine and local anesthetics such as lidocaine and ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ziconotide (Prialt) for Chronic Pain
Article code: 1223d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian